EUVIMEDEUVIMED entdecken
Crossref

Triglyceride-Glucose Index as a Predictor of Cardiovascular, Renal, and Mortality Outcomes in Patients with Type 2 Diabetes and Metabolic Syndrome

Lu Yali, I Nyoman Ehrich Lister, Florenly Florenly

International Journal of Drug Delivery Technology · 19.05.2026 · 16 (30s)

DOI: 10.25258/ijddt.16.30s.71 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 19.05.2026. Verfasst von Lu Yali und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A low-cost insulin resistance surrogate, derived from standard measurements of fasting triglyceride and fasting glucose, has gained interest as the triglyceride-glucose (TyG) index. Its clinical utility is based on its simplicity, particularly in environments where direct measurement of insulin, clamp experiments, or repeat assessment by expert functions are not feasible. This review aims to assess the capacity of the TyG index to predict cardiovascular, kidney, and mortality outcomes in individuals with type 2 diabetes mellitus (T2DM) and those with high-risk cardiometabolic states highly compatible with metabolic syndrome. An intensive literature review was conducted using recent peer-reviewed articles, with preference given to primary cohort analyses and meta-analytic syntheses. The findings section has selected 15 main studies that were critically evaluated for their design, population, adjustment strategy, endpoint definition, and clinical transferability. On the whole, these findings indicate that there is a uniform pattern of association: increased TyG scores, and in part increased cumulative exposure, are associated with increased major adverse cardiovascular events, accelerated renal failure, and increased either all-cause or cardiovascular mortality. Prediction, however, is not uniform across populations. These are most strongly associated in cohorts with existing coronary disease, acute coronary syndromes, chronic kidney disease, inadequate glycaemic regulatory control, or a longer duration of diabetes. Methodological flaws also recur, including retrospective designs, single baseline measurements, uncontrolled confounding, low discrimination, and a concentration of data in East Asian or North American samples. The paper concludes that TyG can only be construed as an applied riskenrichment tool, rather than a test of its own prognostic value. It is most useful when combined with traditional measures of glycaemic burden, kidney disease, obesity, and already established cardiovascular risk, whether or not it is like that.

Zitieren

APA

Yali, L., Lister, I. N. E., & Florenly, F. (2026). Triglyceride-Glucose Index as a Predictor of Cardiovascular, Renal, and Mortality Outcomes in Patients with Type 2 Diabetes and Metabolic Syndrome. International Journal of Drug Delivery Technology, 16(30s). https://doi.org/10.25258/ijddt.16.30s.71

Vancouver

Yali L, Lister INE, Florenly F. Triglyceride-Glucose Index as a Predictor of Cardiovascular, Renal, and Mortality Outcomes in Patients with Type 2 Diabetes and Metabolic Syndrome. International Journal of Drug Delivery Technology. 2026;16(30s). doi:10.25258/ijddt.16.30s.71

BibTeX
@article{Yali2026,
  author = {Yali, Lu and Lister, I Nyoman Ehrich and Florenly, Florenly},
  title = {Triglyceride-Glucose Index as a Predictor of Cardiovascular, Renal, and Mortality Outcomes in Patients with Type 2 Diabetes and Metabolic Syndrome},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {30s},
  doi = {10.25258/ijddt.16.30s.71}
}
Kostenlos starten →